PROM1 and hepatocellular carcinoma: In a phase I clinical trial, the 23 patients with hepatocellular carcinoma received CD133-directed CAR-T cell infusions, and 21 patients had not developed detectable de novo lesions within the observation time frame; thereby, the trial demonstrated feasibility, safety, and efficacy of CD133-directed CAR T-cell therapy in patients [93].